| 摘要 |
PROBLEM TO BE SOLVED: To obtain an agent for ameliorating the ophthalmic nerve disorder of a patient of ophthalmic nerve disorder such as low vision and narrowing of visual field by using a prostanoic acid compound as an active component. SOLUTION: The objective agent contains, as an active component, a prostanoic acid compound of the formula such as a 2-decarboxy-2-(2- carboxyethyl)-prostaglandin compound, an 18,19,20-trinor-17-phenyl-prostaglandin compound, a 16-mono or difluoro-prostaglandin compound, a 13,14-dihydro-15- keto-20-ethyl-prostaglandin compound, a 13,14-dihydro-15-keto-16-mono or difluoro-prostaglandin compound or a 2-decarboxy-2-(2-carboxyethyl)-13,14- dihydro-15-keto-16-mono or difluoro-prostaglandin compound and is administered by instillation, oral administration, intravenous injection, subcutaneous injection and intrarectal administration. In the case of topical instillation, the agent is applied at a rate of 0.01-100μg/eye.
|
